Merck & Co., Inc. (NYSE:MRK) Announces Quarterly Earnings Results

Merck & Co., Inc. (NYSE:MRKGet Rating) issued its earnings results on Thursday. The company reported $2.14 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.83 by $0.31, MarketWatch Earnings reports. The business had revenue of $15.90 billion during the quarter, compared to analyst estimates of $14.64 billion. Merck & Co., Inc. had a return on equity of 47.24% and a net margin of 26.02%. Merck & Co., Inc.’s revenue for the quarter was up 31.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.40 earnings per share. Merck & Co., Inc. updated its FY22 guidance to $7.24-7.36 EPS.

Merck & Co., Inc. stock traded up $4.28 on Thursday, hitting $88.69. 1,468,177 shares of the stock traded hands, compared to its average volume of 12,065,584. The company has a current ratio of 1.27, a quick ratio of 1.02 and a debt-to-equity ratio of 0.80. The firm has a market cap of $224.19 billion, a P/E ratio of 16.42, a price-to-earnings-growth ratio of 1.40 and a beta of 0.45. The business’s fifty day simple moving average is $81.04 and its 200 day simple moving average is $79.98. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $91.40.

Institutional investors have recently made changes to their positions in the business. OLD Mission Capital LLC purchased a new position in Merck & Co., Inc. during the third quarter valued at $247,000. Bell Rock Capital LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $233,000. First Community Trust NA purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $127,000. Ulland Investment Advisors LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $75,000. Finally, Carroll Investors Inc purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $48,000. 72.05% of the stock is owned by institutional investors and hedge funds.

MRK has been the subject of several research reports. Morgan Stanley cut their target price on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. StockNews.com initiated coverage on Merck & Co., Inc. in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. JPMorgan Chase & Co. cut their target price on Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a research note on Friday, January 28th. Barclays increased their price objective on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, April 12th. Finally, Mizuho started coverage on Merck & Co., Inc. in a research note on Friday, April 1st. They set a “buy” rating and a $100.00 price objective for the company. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $90.69.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Earnings History for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.